Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer

Minerva Endocrinologica

Volumn 39, Issue 1, 2014, Pages 59-65

  Mousavi, Z ^a   Dourandish, L ^a   Rokni, H ^a   Sadeghi, R ^b   Rasoul Zakavi, S ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Metformin; Thyroid neoplasms; Thyrotropin

Indexed keywords

LEVOTHYROXINE; METFORMIN; PLACEBO; THYROID HORMONE; THYROTROPIN;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADD ON THERAPY; ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DRUG DOSE REDUCTION; DRUG EFFECT; DYSPNEA; FEMALE; FOLLICULAR CARCINOMA; FOLLOW UP; HEART PALPITATION; HEART RATE; HUMAN; INCREASED APPETITE; LIOTHYRONINE BLOOD LEVEL; MALE; PAPILLARY CARCINOMA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SWEATING; TACHYCARDIA; THYROID HORMONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREMOR; WEAKNESS;

ADENOCARCINOMA, FOLLICULAR; ADULT; BODY WEIGHT; CARCINOMA, PAPILLARY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; HYPERTHYROIDISM; MALE; METFORMIN; MIDDLE AGED; SINGLE-BLIND METHOD; THYROID HORMONES; THYROID NEOPLASMS; THYROTROPIN; THYROXINE; TREATMENT FAILURE; YOUNG ADULT;

EID: 84898758480     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA: a cancer journal for clinicians 2005;55:10.
2. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
3. Pacini F, Schlumberger M, Dralle H, Ilisea R, Smith Y, Viersinga V. [European consensus on the management of patients with differentiated carcinoma of the thyroid from follicular epithelium]. Vestn Khir Im I I Grek 2008;167:52-6.
4. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nature Reviews Endocrinology 2005;1:32-40.
5. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
6. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev 2005;26:704-28. (Pubitemid 41127279)
7. Sgarbi JA, Villaca FG, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 2003;88:1672-7. (Pubitemid 36623386)
8. Donangelo I, Braunstein GD. Update on subclinical hyperthyroidism. Am Fam Physician 2011;83:933-8.
9. Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010;20:135-46.
10. Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab 2006;91:225-7. (Pubitemid 43069142)
11. Isidro ML, Penín MA, Nemiña R, Cordido F. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 2007;32:79-82. (Pubitemid 350242550)
12. Maudar V, Winters SJ, Villafuerte BC. Hot flashes and fatigue relieved by metformin. Endocr Pract 2009;15:30-4.
13. Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab 2009;23:793-800.
14. Crooks J, Murray IP, Wayne EJ. Statistical methods applied to the clinical diagnosis of thyrotoxicosis. Q J Med 1959;28:211-34.
15. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews 2008;29:76-131. (Pubitemid 351252748)
16. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996;81:4278-89. (Pubitemid 26412030)
17. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994;130:350-6. (Pubitemid 24135720)
18. Campbell RK, White JR Jr, Saulie BA. Metformin: a new oral biguanide. Clin Ther 1996;18:360-71; discussion 59.
19. Roberto C, Luciana P, Francesco C, Lucia S, Miriam N, Pierina R, editors. Thyrotropin suppression by metformin in a cohort of patients with differentiated thyroid cancer in follow-up 2009.
20. Cappelli C, Rotondi M, Pirola I, Agosti B, Gandossi E, Valentini U et al. TSH-Lowering Effect of Metformin in Type 2 Diabetic Patients. Diabetes Care 2009;32:1589.
21. Rezzónico J, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord 2010:1595-607.
22. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9:1092.
23. Rotondi M, Cappelli C, Magri F, Botta R, Dionisio R, Iacobello C et al. Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. Clin Endocrinol 2011;75:378-81.
24. Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabete Metab 1979;5.233-45.